Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS (U-Protect)
Primary Purpose
Respiratory Distress Syndrome, Adult
Status
Terminated
Phase
Not Applicable
Locations
Singapore
Study Type
Interventional
Intervention
Prismalung
Ultra-protective ventilation
Conventional Lung Protective Ventilation
Sponsored by
About this trial
This is an interventional treatment trial for Respiratory Distress Syndrome, Adult
Eligibility Criteria
Inclusion Criteria:
- Admitted to MICU with respiratory failure and intubated
- ARDS criteria per Berlin definition
- PaO2:FiO2 ratio ≤ 200 mmHg for > 6 hours with FiO2 ≥0.5
- Expected to require mechanical ventilation for >48 hours
- Reversible disease
Exclusion Criteria:
- Anticoagulation contraindicated
- Proven HIT
- Unable to obtain central venous access
- Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO
- Home oxygen use
- Severe COPD
- Interstitial lung disease
- > 7 days of mechanical ventilation
- Immunocompromised patient (bone marrow, untreated HIV, PJP)
- Advanced malignancy with life expectancy ≤ 6months
Sites / Locations
- National University Hospital
- Ng Teng Fong General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Conventional lung protective ventilation
Ultra-protective ventilation
Arm Description
Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
Outcomes
Primary Outcome Measures
Plateau Pressure
Ability to achieve a plateau pressure of </=25 cmH20 in the intervention arm
Secondary Outcome Measures
Length of stay in ICU stay
Length of hospital stay
Mortality
ICU mortality, hospital mortality, 30 day, 60 day and 90 day mortality
Cardiac Imaging
Echocardiogram data will be collected before prone position, after prone positioning and following initiation of ultra-protective ventilation
Extracorporeal carbon dioxide removal related complications
Complications or adverse events related to ECCO2R and associated anticoagulation
Ventilator free days
All severe adverse events
Number of patient meeting proning criteria in each group
Ability to successfully prone
Incidence of dialysis in ICU, and ability to successfully initiate
Incidence of referrals for ECMO
Rate and reasons for declining consent to study participation
Enrolment rates
Lung recruitability
Ventilation parameters
Data download from mechanical ventilation
Ventilator associated pneumonia rates
Barotrauma complications
Biomarkers of Pulmonary Inflammation
Serum will be drawn and stored for pulmonary biomarkers analysis at the above time points
Full Information
NCT ID
NCT02252094
First Posted
September 17, 2014
Last Updated
September 10, 2020
Sponsor
National University Health System, Singapore
Collaborators
Baxter Healthcare Corporation
1. Study Identification
Unique Protocol Identification Number
NCT02252094
Brief Title
Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS
Acronym
U-Protect
Official Title
Ultra-protective Pulmonary Ventilation Supported by Low Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) and Prone Positioning for ARDS; a Pilot Study.
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
Device no longer available in Singapore
Study Start Date
May 22, 2017 (Actual)
Primary Completion Date
May 31, 2019 (Actual)
Study Completion Date
May 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National University Health System, Singapore
Collaborators
Baxter Healthcare Corporation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study evaluates the use of ultra-protective ventilation, where very low ventilation volumes are used, in patients with severe acute respiratory distress syndrome (ARDS) meeting criteria to nurse in the prone position. Half the patients will receive ultra-protective ventilation support by extracorporeal carbon dioxide removal, while the other half will receive conventional lung protective ventilation.
Detailed Description
Current best practices for management of severe ARDS include lung protective ventilation and nursing in the prone position. However, the best lung protective strategy is not currently established and using smaller ventilation volumes than standard lung protective ventilation suggest lung recovery is improved.
Application of smaller ventilation volumes requires extracorporeal carbon dioxide removal, using a device similar to a dialysis to remove carbon dioxide directly from the blood. One such device in the Prismalung, it removes blood through a catheter, much like a dialysis catheter, pumps it through a gas exchange cartridge which removes carbon dioxide. The gas exchange cartridge functions in a similar way to a dialysis filter, except it allow gases to pass through, unlike dialysis filters which allow passage of fluid and small molecules.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Distress Syndrome, Adult
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Data analysis will be blinded.
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Conventional lung protective ventilation
Arm Type
Active Comparator
Arm Description
Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
Arm Title
Ultra-protective ventilation
Arm Type
Experimental
Arm Description
Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
Intervention Type
Device
Intervention Name(s)
Prismalung
Other Intervention Name(s)
Low flow extracorporeal carbon dioxide removal, Respiratory Dialysis
Intervention Description
Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
Intervention Type
Other
Intervention Name(s)
Ultra-protective ventilation
Intervention Description
Ventilation with </= 3ml/kg predicted body weight
Intervention Type
Other
Intervention Name(s)
Conventional Lung Protective Ventilation
Intervention Description
Ventilation with 6ml/kg predicted body weight
Primary Outcome Measure Information:
Title
Plateau Pressure
Description
Ability to achieve a plateau pressure of </=25 cmH20 in the intervention arm
Time Frame
Duration of ventilation for severe ARDS, expected average time 10 days
Secondary Outcome Measure Information:
Title
Length of stay in ICU stay
Time Frame
Duration of patient stay in ICU, expected average stay 2 weeks
Title
Length of hospital stay
Time Frame
Duration of patient stay in hospital
Title
Mortality
Description
ICU mortality, hospital mortality, 30 day, 60 day and 90 day mortality
Time Frame
Monitored for 3 months
Title
Cardiac Imaging
Description
Echocardiogram data will be collected before prone position, after prone positioning and following initiation of ultra-protective ventilation
Time Frame
One data set per patient during first 72 hours
Title
Extracorporeal carbon dioxide removal related complications
Description
Complications or adverse events related to ECCO2R and associated anticoagulation
Time Frame
Duration of severe ARDS, expected average time frame 10 days
Title
Ventilator free days
Time Frame
28 days
Title
All severe adverse events
Time Frame
Duration of ICU stay (anticipate average stay 1-2 weeks)
Title
Number of patient meeting proning criteria in each group
Time Frame
Duration of ICU stay
Title
Ability to successfully prone
Time Frame
Duration of ICU stay
Title
Incidence of dialysis in ICU, and ability to successfully initiate
Time Frame
Duration of ICU stay
Title
Incidence of referrals for ECMO
Time Frame
Duration of ICU stay
Title
Rate and reasons for declining consent to study participation
Time Frame
First 48 hours
Title
Enrolment rates
Time Frame
First 48 hours
Title
Lung recruitability
Time Frame
Duration of ICU stay
Title
Ventilation parameters
Description
Data download from mechanical ventilation
Time Frame
Duration of mechanical ventilation
Title
Ventilator associated pneumonia rates
Time Frame
Duration of ICU stay
Title
Barotrauma complications
Time Frame
Duration of ICU stay
Title
Biomarkers of Pulmonary Inflammation
Description
Serum will be drawn and stored for pulmonary biomarkers analysis at the above time points
Time Frame
Day 0, 4 and 7
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Admitted to MICU with respiratory failure and intubated
ARDS criteria per Berlin definition
PaO2:FiO2 ratio ≤ 200 mmHg for > 6 hours with FiO2 ≥0.5
Expected to require mechanical ventilation for >48 hours
Reversible disease
Exclusion Criteria:
Anticoagulation contraindicated
Proven HIT
Unable to obtain central venous access
Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO
Home oxygen use
Severe COPD
Interstitial lung disease
> 7 days of mechanical ventilation
Immunocompromised patient (bone marrow, untreated HIV, PJP)
Advanced malignancy with life expectancy ≤ 6months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew E Cove, MBChB
Organizational Affiliation
National University Health System
Official's Role
Principal Investigator
Facility Information:
Facility Name
National University Hospital
City
Singapore
ZIP/Postal Code
119074
Country
Singapore
Facility Name
Ng Teng Fong General Hospital
City
Singapore
ZIP/Postal Code
609606
Country
Singapore
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19741487
Citation
Terragni PP, Del Sorbo L, Mascia L, Urbino R, Martin EL, Birocco A, Faggiano C, Quintel M, Gattinoni L, Ranieri VM. Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology. 2009 Oct;111(4):826-35. doi: 10.1097/ALN.0b013e3181b764d2.
Results Reference
background
PubMed Identifier
23306584
Citation
Bein T, Weber-Carstens S, Goldmann A, Muller T, Staudinger T, Brederlau J, Muellenbach R, Dembinski R, Graf BM, Wewalka M, Philipp A, Wernecke KD, Lubnow M, Slutsky AS. Lower tidal volume strategy ( approximately 3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med. 2013 May;39(5):847-56. doi: 10.1007/s00134-012-2787-6. Epub 2013 Jan 10.
Results Reference
background
Learn more about this trial
Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS
We'll reach out to this number within 24 hrs